01
Oct

Portola Pharmaceuticals’ antidote to Big Pharma’s latest crop of blockbuster blood thinners hit the mark in its first Phase III trial, clearing the way for an FDA submission next year.

…read more

Source: Portola’s ‘breakthrough’ anti-anticoagulant clears a Phase III hurdle

    

0 No comments